In 2020, we awarded £250,000 to AAAMD towards the first two stages (over three years) of the organisation’s strategy involving validating existing data and creating a large-scale, data-driven project using participants’ data and Artificial Intelligence for diagnosis of early age related macular degeneration. This work is necessary for the project, enabling AAAMD to move towards the clinical trial stage.

Funding the research will build on our existing support for non-medical research in the UK visual impairment sector, which continues to be underfunded compared with other diseases and disabilities – as was originally identified in the New Philanthropy Capital report funded by The Foundation in 2013 (available on our website). This will be a further, important piece of work aimed at strengthening the case for increased investment in eye research.